The New York State Cellular Therapy Consortium

This is a clinically oriented educational program intended for hematologists, oncologists, pharmacists, pathologists, and other healthcare professionals that may diagnose, treat, or manage patients with cancer. The goal is to educate participants about new cellular therapies, both those that are currently available and those that are set to become available in the near future.

Target audience

Hematologists, oncologists, pharmacists, pathologists and other cancer health care professionals, including PAs, NPs, and RNs.

Educational goals


Enhancing Cell Therapy at Roswell Park

Renier Brentjens, MD, PhD

Renier Brentjens, MD, PhD

Deputy Director
Professor of Oncology
Chair, Department of Medicine
Department of Immunology
The Katherine Anne Gioia Endowed Chair in Cancer Medicine


Solid Tumor Cell Therapies

Anuradha Krishnamurthy, MBBS

Anuradha Krishnamurthy, MBBS

Assistant Professor of Oncology
Department of Medicine
Associate Director of Early Phase Clinical Trials for Solid Tumor Cell Therapies

TIL Cell Therapy Clinical Data Summary

Igor Puzanov, MD, MSCI, FACP

Igor Puzanov, MD, MSCI, FACP

Senior Vice President, Clinical Investigation
Professor of Oncology, Department of Medicine
Director, Center for Early Phase Clinical Trials
Chief, Early Phase Clinical Trials Division
Chief, Melanoma Section

Questions and Answers

Renier Brentjens, MD, PhD

Renier Brentjens, MD, PhD

Deputy Director
Professor of Oncology
Chair, Department of Medicine
Department of Immunology
The Katherine Anne Gioia Endowed Chair in Cancer Medicine
Igor Puzanov, MD, MSCI, FACP

Igor Puzanov, MD, MSCI, FACP

Senior Vice President, Clinical Investigation
Professor of Oncology, Department of Medicine
Director, Center for Early Phase Clinical Trials
Chief, Early Phase Clinical Trials Division
Chief, Melanoma Section
Anuradha Krishnamurthy, MBBS

Anuradha Krishnamurthy, MBBS

Assistant Professor of Oncology
Department of Medicine
Associate Director of Early Phase Clinical Trials for Solid Tumor Cell Therapies
Jens Hillengass, MD, PhD

Jens Hillengass, MD, PhD

Chief of Myeloma, Professor of Oncology